This review is a product review of the use of Crizotinib (Xalkori) for the treatment of ROS1-positive advanced NSCLC.
The review covers treatment of gene mutations in NSCLC, burden of disease in Australia, drug pharmacodynamics, dosage and efficacy. It also provides key studies, commentary and recommendations from Dr Malinda Itchins, a practicing Medical Oncologist at Northern Cancer Institute, St Leonards and North Shore Private Hospital and an active member of the Australasian Lung Cancer Trials Group (ALTG).
Please login below to download this issue (PDF)